Response to comment on Moore et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes care 2013;36:2981-2987.

We thank Goodarzi (1) for his interest in our work (2) and recognize that we agree with most of the criticisms leveled at our study. Indeed, most of the points raised were acknowledged in our original work. There is a need to test the issues raised more robustly—a point on which we agree. Goodarzi highlights that B12 levels may be unrelated to the association of metformin with cognitive function. We do …